Ferroptotic Neurons
Introduction
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Ferroptotic Neurons</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Ferroptosis</td>
</tr>
<tr>
<td class="label">Morphology</td>
<td>Shrunken mitochondria</td>
</tr>
<tr>
<td class="label">Membrane</td>
<td>Intact</td>
</tr>
<tr>
<td class="label">Energy</td>
<td>ATP-dependent</td>
</tr>
<tr>
<td class="label">Caspases</td>
<td>Not required</td>
</tr>
<tr>
<td class="label">Iron</td>
<td>Required</td>
</tr>
<tr>
<td class="label">Lipid ROS</td>
<td>Accumulation</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Ferrostatin-1</td>
<td>Lipid ROS</td>
</tr>
<tr>
<td class="label">Liproxstatin-1</td>
<td>Lipoxygenases</td>
</tr>
<tr>
<td class="label">SLC-1</td>
<td>System Xc-</td>
</tr>
<tr>
<td class="label">RSL3 analogs</td>
<td>GPX4</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Edaravone</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>MS</td>
</tr>
<tr>
<td class="label">Vitamin E</td>
<td>AD</td>
</tr>
</table>
Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent lipid peroxidation accumulation and the collapse of cellular antioxidant defenses.[@li2019] First described in 2012 by Dixon et al. (2012), ferroptosis has emerged as a critical mechanism in neuronal death across multiple neurodegenerative diseases[@dixon2012] including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), and Multiple System Atrophy (MSA) (Stockwell et al., 2017). Unlike apoptosis, ferroptosis is morphologically and biochemically distinct, featuring shrunken mitochondria with normal-sized nuclei and requiring iron-catalyzed lipid peroxidation rather than caspase activation.
The discovery of ferroptosis has revolutionized our understanding of regulated cell death in the nervous system and opened therapeutic avenues for neurodegenerative disease intervention. Growing evidence suggests that ferroptotic neuronal death contributes significantly to the progressive loss of specific neuronal populations in these disorders, making it a high-priority therapeutic target.
Molecular Mechanisms of Ferroptosis in Neurons
Neuronal ferroptosis is initiated by abnormal iron accumulation within cells. The brain has particularly high iron requirements for oxidative metabolism, myelogenesis, and neurotransmitter synthesis, making neurons especially vulnerable to iron dysregulation (Masaldan et al., 2019).
Key Iron-Related Changes:
- Increased intracellular iron: Upregulation of transferrin receptor 1 (TFR1) and ferritin leads to iron accumulation in neurons
- Dysregulated ferritin: Altered ferritin expression affects iron storage and release
- Neuromelanin binding: In dopamine neurons, neuromelanin serves as both an iron sink and source depending on cellular conditions
- Fenton chemistry: Fe2+ catalyzes the conversion of hydrogen peroxide to hydroxyl radicals via the Fenton reaction
Iron Import/Export Pathways:
- Transferrin (Tf)-TFR1 mediated import
- DMT1 (divalent metal transporter 1)
- Ferroportin (FPN) mediated export
- Hepcidin regulation of ferroportin
Lipid Peroxidation Cascade
The central event in ferroptosis is iron-dependent lipid peroxidation, particularly of polyunsaturated fatty acids (PUFAs) in cellular membranes (Fedorova et al., 2019).
Key Enzymes and Pathways:
- GPX4 (Glutathione Peroxidase 4): The primary enzyme that reduces lipid peroxides. GPX4 deletion or inhibition triggers ferroptosis
- SLC7A11 (System Xc-): Cystine/glutamate antiporter that provides cysteine for glutathione synthesis. Inhibition causes ferroptosis
- ALOX12/ALOX15: Lipoxygenases that catalyze PUFA peroxidation
- ACSL4 (Acyl-CoA Synthetase Long-Chain Family Member 4): Required for incorporating PUFAs into phospholipids
Lipid Peroxidation Products:
- Phosphatidylethanolamine hydroperoxides (PE-OOH)
- Malondialdehyde (MDA)
- 4-hydroxynonenal (4-HNE)
- Isoprostanes
Regulatory Networks
Multiple signaling pathways converge on ferroptosis regulation:
Promoting Pathways:
- NRF2 deficiency: Reduces antioxidant response elements (AREs) (Wang et al., 2022)
- p53 activation: Suppresses SLC7A11 expression
- HIF1alpha stabilization: Under hypoxic conditions
- Autophagy: Selective autophagy of ferritin (ferritinophagy) increases intracellular iron
Inhibiting Pathways:
- NRF2 activation: Increases antioxidant gene expression
- GPX4 activity
- SLC7A11 function
- Ferroptosis suppressor proteins (FSP1, DHODH)
Ferroptosis in Specific Neurodegenerative Diseases
Alzheimer's Disease
In Alzheimer's disease, ferroptosis contributes to neuronal loss through multiple mechanisms (Mahoney-Sánchez et al., 2021):
Pathological Links:
- Amyloid-beta interaction: Aβ directly binds transferrin and alters iron metabolism
- Iron accumulation: Excess iron in brain regions with amyloid plaques
- Lipid peroxidation: Elevated 4-HNE and isoprostanes in AD brains
- GPX4 reduction: Decreased GPX4 in AD temporal cortex
- Tau pathology: Iron promotes tau hyperphosphorylation and aggregation
Evidence:
- Post-mortem AD brains show increased iron in neurons and glia
- Elevated lipid peroxidation markers in cerebrospinal fluid (CSF)
- Animal models demonstrate ferroptosis inhibition reduces neuronal death
- Genetic studies link ferroptosis-related genes to AD risk
Regional Vulnerability:
- Hippocampal CA1 neurons particularly susceptible
- Entorhinal cortex shows early iron accumulation
- Frontal cortex affected in later stages
Therapeutic Implications:
- Iron chelation with deferoxamine shows cognitive benefits in clinical trials
- Liproxstatin-1 reduces neuronal loss in AD mouse models
- Vitamin E supplementation has shown cognitive benefit in some AD trials
Clinical Trials:
- Deferoxamine trials (1990s-2000s) showed modest cognitive benefit
- Current trials testing newer chelators ( NCT05745621, NCT05892321)
- Combination approaches under investigation
Parkinson's Disease
Parkinson's disease shows particularly strong evidence for ferroptotic mechanisms (Do Van et al., 2016):
Pathological Links:
- Neuromelanin iron binding: The substantia nigra pars compacta (SNc) contains high iron
- Neuromelanin degradation: Releases iron during neurodegeneration
- Lipid peroxidation: Increased 4-HNE in SNc of PD patients
- GPX4 alterations: Changed GPX4 expression in PD brains
- System Xc- dysfunction: Altered cystine uptake in PD models
Evidence:
- Elevated iron in SNc demonstrated by MRI
- Increased lipid peroxidation markers in PD CSF
- Genetic links to iron metabolism genes (PARK8/LRRK2, PARK7/DJ-1)
- Ferroptosis inhibitors protect dopaminergic neurons in vitro
- Post-mortem studies show GPX4 reduction in SNc
Regional Vulnerability:
- Dopaminergic neurons in SNc most affected
- Locus coeruleus also shows iron accumulation
- Dorsal motor nucleus of vagus affected
Therapeutic Approaches:
- Deferoxamine clinical trials for PD (mixed results)
- Iron chelation strategies with newer agents
- NRF2 activators in trials
- GPX4-enhancing compounds in development
Clinical Trials:
- Deferasirox trial (NCT01737030) - completed
- Novel chelator trials ongoing ( NCT06018291)
Amyotrophic Lateral Sclerosis
Ferroptosis is increasingly recognized in ALS (Gladstone et al., 2021):
Evidence:
- ALS mouse models show lipid peroxidation accumulation
- GPX4 reduction in motor neurons
- Iron accumulation in spinal cord
- CSF biomarkers of ferroptosis
SOD1 Models:
- Lipid peroxidation markers elevated
- GPX4 activity reduced
- System Xc- dysfunction present
- Ferrostatin-1 extends survival
C9orf72 Models:
- Repeat expansion affects iron metabolism
- Ferroptosis-related gene expression altered
- Dipeptide repeat proteins affect system Xc-
Therapeutic Targets:
- Ferric citrate reduces progression in mouse models (Devos et al., 2022)
- Liproxstatin-1 extends survival in SOD1 mice
- Ferroptosis-related genes (GPX4, SLC7A11) as therapeutic targets
Clinical Trials:
- Edaravone approved (has antioxidant properties)
- Ferric citrate trial planned
- Combination trials in design
Huntington's Disease
Huntington's disease demonstrates ferroptotic features (Borghi et al., 2022):
Evidence:
- Mutant huntingtin affects iron metabolism
- Altered GPX4 and system Xc-
- Lipid peroxidation in HD brain
- Energy metabolism impairment promoting ferroptosis
- Elevated iron in striatum
Mechanisms:
- Mutant huntingtin increases TF1 expression
- Impairs mitochondrial function
- Reduces system Xc- activity
- Alters NRF2 localization
Therapeutic Targets:
- Iron chelation strategies
- Lipid peroxidation inhibitors
- NRF2 activators
- Energy metabolism modulators
Multiple System Atrophy
MSA shows ferroptosis involvement (Chen et al., 2021):
Evidence:
- Oligodendrocyte degeneration involves ferroptosis
- Iron accumulation in striatum
- Oligodendrocyte-specific vulnerability
- Myelin breakdown products promote ferroptosis
Subtypes:
- MSA-C (cerebellar): Cerebellar neurons affected
- MSA-P (parkinsonian): Striatal neurons affected
- Both show iron dysregulation
Therapeutic Approaches:
- Iron chelation
- Lipid peroxidation inhibition
- Oligodendrocyte protection
Stroke and Traumatic Brain Injury
Additional neurological conditions where ferroptosis plays a role (Gao et al., 2019; Anthonym et al., 2020):
Ischemic Stroke:
- Reperfusion injury involves ferroptosis
- Iron released from hemoglobin
- GPX4 inhibition contributes
- Ferroptosis inhibitors reduce infarct size
Hemorrhagic Stroke:
- Iron from blood cells accumulates
- Perihematomal region shows ferroptosis
- Chelation beneficial in models
Traumatic Brain Injury:
- Secondary injury involves ferroptosis
- Iron accumulation post-injury
- Ferroptosis contributes to chronic deficits
Mechanistic Pathways - Detailed Analysis
System Xc- (SLC7A11/SLC3A2) Complex
The cystine/glutamate antiporter system Xc- is critical for ferroptosis regulation (Liu et al., 2020):
Structure:
- Heterodimer of SLC7A11 (xCT) and SLC3A2 (4F2hc)
- 12 transmembrane domains
- Oxidized form transports cystine
Function:
- Imports cystine in exchange for glutamate export
- 1 cystine : 1 glutamate
- Rate depends on cystine gradient
Neurodegeneration Links:
- SLC7A11 expression reduced in PD
- Genetic variants linked to ALS risk
- System Xc- dysfunction promotes ferroptosis
Therapeutic Targeting:
- Inhibitors: Erastin, sulfasalazine
- Activators: N-acetylcysteine, ebselen
GPX4 Pathway
Glutathione peroxidase 4 is the central ferroptosis regulator:
Catalytic Mechanism:
- Uses GSH to reduce lipid peroxides
- Produces GSSG as product
- Selenocysteine active site
Isoforms:
- Cytosolic GPX4 (main form)
- Phospholipid hydroperoxide GPX4 (PHGPX)
- Mitochondrial GPX4
Regulation:
- Transcription via NRF2
- Post-translational modifications
- Selenoprotein expression
In Neurodegeneration:
- GPX4 reduced in AD, PD, ALS
- Post-translational modifications affect activity
- Genetic variants may increase risk
Neuronal iron handling is highly regulated (Masaldan et al., 2019; Ayton et al., 2023):
Import:
- Transferrin receptor 1 (TFR1) main pathway
- Non-transferrin bound iron (NTBI) via DMT1
- Ferritin can chaperone iron
Storage:
- Ferritin (FTH1/FTL) stores iron
- Heavy and light subunits
- Can store 4500 iron atoms
Export:
- Ferroportin (FPN) main exporter
- Requires hepcidin regulation
- Ceruloplasmin aids oxidation
Special Considerations:
- High metabolic demand for iron
- Myelin production requires iron
- Neurotransmitter synthesis needs iron
Ferroptosis Signaling Pathways
NRF2 Pathway:
- Master regulator of antioxidant response
- Controls GPX4, SLC7A11, FTH1
- Keap1-NRF2 axis regulation
- NRF2 activators prevent ferroptosis
p53 Pathway:
- p53 suppresses SLC7A11 transcription
- p53 activation promotes ferroptosis
- p53-independent roles also exist
AMPK Pathway:
- Energy stress affects ferroptosis
- AMPK phosphorylation affects synthesis
- Autophagy modulates susceptibility
Mermaid Pathway Diagrams
Mermaid diagram (expand to render)
Mermaid diagram (expand to render)
Comparison of Cell Death Pathways
Clinical Biomarkers and Diagnosis
Cerebrospinal Fluid Markers
CSF biomarkers provide window into ongoing neuronal injury (Connelly et al., 2019):
Established Markers:
- Lipid peroxidation products: 4-HNE, MDA, isoprostanes
- 4-HNE-protein adducts elevated in AD, PD
- Isoprostanes reflect oxidative stress
- Correlate with disease severity
- Iron indices: Ferritin, transferrin
- Elevated ferritin in some conditions
- Transferrin saturation changes
- GPX4 activity: Challenging to measure directly
Emerging Markers:
- Phospholipid hydroperoxides detection
- Free iron imaging probes (FeRhoNox)
- System Xc- functional assays
Imaging Biomarkers
Quantitative Susceptibility Mapping (QSM) MRI:
- Direct iron quantification in brain
- Regional sensitivity across brain regions
- Correlates with clinical measures in PD and AD
R2* Relaxometry:
- Iron-sensitive MRI technique
- Substantia nigra iron measurement in PD
- Correlation with disease duration and severity
PET Tracers:
- Ferroptosis-specific tracers in development
- Not yet validated for clinical use in neurodegeneration
Clinical Utility
Current biomarker applications:
- Trial enrichment: Patient selection based on biomarkers
- Target engagement: Measure drug effects
- Disease progression: Track changes over time
- Prognostic utility: Risk stratification in early disease
Therapeutic Agents in Detail
Iron Chelators
Deferoxamine (DFO):
- Classic iron chelator with established mechanisms
- Poor BBB penetration limits efficacy
- Subcutaneous administration required
- Used historically in PD trials (mixed results)
- Limited brain efficacy at therapeutic doses
Deferasirox (Jadenu):
- Oral chelator with better compliance
- Improved tolerance profile
- Modest brain penetration achieved
- Clinical trials in PD and ALS ongoing
- Acceptable safety profile established
Clioquinol:
- 8-hydroxyquinoline compound
- Multiple metal binding capacity (Cu, Zn, Fe)
- Promotes metalloprotein function
- Phase trials conducted in AD with mixed outcomes
PBT434:
- Novel quinoline derivative
- Enhanced brain-penetrant properties
- Strong preclinical promise
- Entering clinical trials soon
Antioxidants
Vitamin E:
- Chain-terminating antioxidant mechanism
- Clinical trials in AD showed benefit in some studies
- May slow disease progression modestly
- Safe at high doses with monitoring
Edaravone:
- FDA-approved for ALS treatment
- Multiple antioxidant properties
- NRF2 activation contributes to efficacy
- Demonstrated modest efficacy in ALS trials
Ferrostatin-1:
- Potent ferroptosis inhibitor
- Radical trapping mechanism
- Excellent efficacy in disease models
- Poor drug-like properties limit clinical use
Liproxstatin-1:
- Lipoxygenase inhibition activity
- Improved brain-penetrant properties
- Strong preclinical efficacy
- Significant clinical development potential
NRF2 Activators
Sulforaphane:
- Broccoli-derived compound
- Potent NRF2 activation
- Multiple antioxidant targets
- Active clinical investigation for neurodegeneration
Dimethyl fumarate:
- Approved treatment for MS
- Demonstrated NRF2 effects
- Potential to reduce ferroptosis
- Well-established safety profile
System Xc- Modulators
N-acetylcysteine (NAC):
- Glutathione precursor pathway
- Alternative cystine source
- Used in psychiatric conditions
- Limited efficacy in neurodegeneration trials
Ebselen:
- GPX4 mimetic compound
- Multi-faceted antioxidant effects
- Active clinical trials in PD
- Favorable safety profile established
Genetic Risk Factors
GWAS Findings
Genome-wide association studies increasingly implicate ferroptosis-related genes in neurodegenerative disease risk:
Alzheimer's Disease:
- ABCA7 influences lipid transport
- CLU (clusterin) modifies risk
- PICALM affects clathrin function
Parkinson's Disease:
- PARK7 (DJ-1) impacts antioxidant function
- PARK8 (LRRK2) shows iron metabolism links
- GBA affects lipid handling
ALS:
- C9orf72 repeat expansion mechanism
- SOD1 modifies antioxidant function
- OPTN influences autophagy
Gene Expression Studies
RNA-seq analysis in neurodegeneration reveals:
- GPX4 expression reduced across disease conditions
- SLC7A11 downregulated specifically in PD
- Iron metabolism genes show altered expression
- ALOX15 upregulated in affected tissues
Therapeutic Development Pipeline
Preclinical Candidates
Clinical Candidates
Morphological and Biochemical Hallmarks
Cellular Morphology
Ferroptotic neurons exhibit distinctive features:
- Mitochondria: Small, electron-dense, wrinkled membrane
- Nucleus: Normal size with intact membrane (unlike apoptosis)
- Cytoplasm: Electron-dense with lipid droplets
- Membrane: Intact plasma membrane (unlike necrosis)
- No apoptotic bodies: Distinct from apoptosis
Biochemical Markers
In Situ Markers:
- GPX4 loss
- ACSL4 upregulation
- Lipid ROS accumulation (BODIPY-C11)
- Free iron increase (FeRhoNox)
Soluble Biomarkers:
- Increased lipid peroxidation products in CSF (Connelly et al., 2019)
- Decreased GPX4 activity
- Altered iron indices
Therapeutic Strategies
Iron Chelation
Clinical Approaches:
- Deferoxamine (DFO): Iron chelator, shown benefit in PD and AD trials
- Deferasirox (Jadenu): Oral iron chelator
- Clioquinol: 8-hydroxyquinoline with iron chelation properties
- PBT434: Novel brain-penetrant iron chelator
Considerations:
- Blood-brain barrier penetration critical
- Need to balance iron chelation with essential functions
- Timing of intervention matters
Lipid Peroxidation Inhibitors
Direct Inhibitors:
- Ferrostatin-1: Potent peroxyl radical scavenger
- Liproxstatin-1: Inhibits lipid ROS generation
- Vitamin E: Chain-terminating antioxidant
- Edaravone: Approved for ALS, has antioxidant properties
Mechanistic Inhibitors:
- Selenium: Cofactor for GPX4 activity
- Statins: Pleiotropic antioxidant effects
System Xc- Modulation
Approaches:
- Sulfasalazine: System Xc- inhibitor (use with caution)
- Ebselen: GPX4 mimic
- N-acetylcysteine: Glutathione precursor
NRF2 Activation
Natural and pharmacological NRF2 activators:
- Sulforaphane: Broccoli-derived NRF2 activator
- Dimethyl fumarate: Approved for MS, activates NRF2
- Oltipraz: NRF2 activator
- CDDO derivatives: Synthetic triterpenoids
Autophagy Modulation
- Chloroquine: Autophagy inhibitor (dual effect)
- Bafilomycin: V-ATPase inhibitor
- 3-Methyladenine: PI3K inhibitor
Genetic Models
- GPX4 conditional knockout: Induces neuronal ferroptosis
- SLC7A11 knockout: System Xc- deficiency models
- Fth1 (ferritin heavy) knockout: Iron accumulation
- NRF2 knockout: Antioxidant deficiency
Chemical Inducers
- Erastin: System Xc- inhibitor
- RSL3: GPX4 inhibitor
- FIN56: GPX4 degradation activator
- Glutamate: Excitotoxicity via system Xc-
Chemical Inhibitors
- Ferrostatin-1: Radical trapping antioxidant
- Liproxstatin-1: Lipoxygenase inhibitor
- Deferoxamine: Iron chelator
- Vitamin E: Antioxidant
Diagnostic and Prognostic Biomarkers
Cerebrospinal Fluid Biomarkers
Based on current research, potential biomarkers include:
- Lipid peroxidation products: 4-HNE, MDA, isoprostanes
- Iron indices: Ferritin, transferrin
- GPX4 activity: Direct measurement challenging
Imaging Biomarkers
- Quantitative susceptibility mapping (QSM) MRI: Brain iron quantification
- R2* mapping: Iron-sensitive MRI
- PET markers: Under development
Clinical Considerations
- Peripheral biomarkers less reliable: Blood-brain barrier limits translation
- Combination approaches needed: Multiple markers increase specificity
- Timing important: Biomarkers change with disease stage
Research Directions and Future Perspectives
Open Questions
What determines neuronal susceptibility to ferroptosis?
How does ferroptosis interact with other cell death pathways?
Can ferroptosis be selectively triggered in diseased neurons?
What is the temporal relationship between ferroptosis and protein aggregation?
How do genetic risk factors modulate ferroptosis?Emerging Therapeutic Approaches
- Gene therapy: Deliver GPX4 or system Xc-
- Small molecule development: Brain-penetrant ferroptosis inhibitors
- Combination therapies: Chelation plus antioxidant
- Biomarker development: Patient selection for trials
Clinical Trial Considerations
- Patient selection: Based on biomarker evidence
- Timing: Early intervention likely more effective
- Combination approaches: Target multiple pathways
- Biomarker-driven: Use biomarkers for response
Summary
Ferroptosis represents a significant mechanism of neuronal death in neurodegenerative diseases. The iron-dependent lipid peroxidation that defines ferroptosis provides therapeutic targets not addressed by traditional approaches. Key points include:
Evidence: Strong evidence for ferroptosis in AD, PD, ALS, HD, and MSA
Mechanisms: Iron accumulation, lipid peroxidation, GPX4/system Xc- dysfunction
Therapeutic targets: Iron chelation, lipid peroxidation inhibitors, NRF2 activators
Challenges: Biomarker development, patient selection, timing of intervention
Future: Growing therapeutic pipeline and clinical trial potentialAs research progresses, ferroptosis-based therapies may provide meaningful disease modification for neurodegenerative diseases currently lacking effective treatments.
Future Directions
Unmet Needs
Validated biomarkers for patient selection and disease monitoring
Brain-penetrant ferroptosis inhibitors with good drug-like properties
Understanding of ferroptosis crosstalk with other cell death pathways
Temporal mapping of ferroptosis in disease progression
Combination approaches targeting multiple mechanismsResearch Priorities
- Develop sensitive CSF and blood biomarkers for ferroptosis
- Create brain-penetrant small molecule inhibitors
- Identify optimal intervention windows in disease
- Understand interactions with protein aggregation
- Define genetic susceptibility factors
Integration with NeuroWiki
This mechanism connects to multiple NeuroWiki pages:
- [Iron Metabolism](/mechanisms/iron-metabolism) - Central to ferroptosis
- [GPX4](/proteins/gpx4) - Key regulatory enzyme
- [System Xc-](/proteins/slc7a11) - Cystine transporter
- [Alzheimer's Disease](/diseases/alzheimers-disease) - Ferroptosis in AD
- [Parkinson's Disease](/diseases/parkinsons-disease) - Ferroptosis in PD
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - Ferroptosis in ALS
- [Lipid Peroxidation](/mechanisms/lipid-peroxidation) - Core mechanism
Additional Disease Connections
Beyond the major neurodegenerative diseases, ferroptosis contributes to:
Amyotrophic Lateral Sclerosis:
- Motor neuron vulnerability is pronounced
- Lipid peroxidation accumulates in spinal cord
- System Xc- shows reduced activity
- GPX4 expression diminished in models
Multiple System Atrophy:
- Oligodendrocyte sensitivity notable
- Iron accumulates in striatum
- Myelin breakdown enhances vulnerability
Stroke:
- Ischemia-reperfusion triggers ferroptosis
- Ferrostatin-1 reduces infarct size
- Adjunctive therapy potential exists
Traumatic Brain Injury:
- Secondary injury involves ferroptosis mechanisms
- Iron released post-injury worsens outcomes
- Early intervention shows promise
Brain Aging:
- Iron accumulates with normal aging
- GPX4 activity declines
- Ferroptosis vulnerability increases
Model Systems
Cell culture and animal models enable mechanistic investigation:
Cell Lines Used:
- SH-SY5Y human neuroblastoma
- PC12 rat pheochromocytoma
- Primary cortical neurons
- iPSC-derived dopaminergic neurons
Animal Models:
- Transgenic overexpressing mice
- Knockout mouse models
- Chemically induced parkinsonism
- ALS genetic models
This comprehensive mechanistic understanding positions ferroptosis as a high-value therapeutic target in NeuroWiki's mission to map neurodegenerative disease mechanisms.
See Also
Related Hypotheses:
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypotheses/h-seaad-v4-26ba859b)
- [Senescence-Induced Lipid Peroxidation Spreading](/hypotheses/h-7957bb2a)
- [Magnetosonic-Triggered Transferrin Receptor Clustering](/hypotheses/h-aa2d317c)
- [Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics](/hypotheses/h-5ff6c5ca)
- [Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement](/hypotheses/h-57862f8a)
Related Analyses:
- [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013)
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004)
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008)
Related Experiments:
- [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)
- [Ferroptosis Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-ferroptosis-parkinsons)
- [Peroxisome Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-peroxisome-dysfunction-parkinsons)
Pathway Diagram
The following diagram shows the key molecular relationships involving Ferroptotic Neurons discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)